Similar articles

• Spectrum of BCR-ABL kinase domain mutations in patients with chronic myeloid leukemia from India with suspected resistance to imatinib-mutations are rare and have different distributions.

  Markose P, Chendamarai E, Balasubramanian P, Velayudhan SR, Srivastava VM, Mathews V, George B, Viswabandya A, Srivastava A, Chandy M. Markose P, et al. Leuk Lymphoma. 2009 Dec;50(12):2092-5. doi: 10.3109/10428190903332486. Leuk Lymphoma. 2009. PMID: 19925053 No abstract available.
• 3. Imatinib therapy in chronic myelogenous leukemia.

  Jinnai I. Jinnai I. Intern Med. 2007;46(2):95-7. doi: 10.2169/internalmedicine.46.1781. Epub 2007 Jan 15. Intern Med. 2007. PMID: 17220607 Review. No abstract available.
• New tyrosine kinase inhibitors in chronic myeloid leukemia.

  Martinelli G, Soverini S, Rosti G, Cilloni D, Baccarani M. Martinelli G, et al. Haematologica. 2005 Apr;90(4):534-41. Haematologica. 2005. PMID: 15820950
• Advances in treatment of chronic myeloid leukemia with tyrosine kinase inhibitors: the evolving role of Bcr-Abl mutations and mutational analysis.

  Soverini S, Martinelli G, Rosti G, Iacobucci I, Baccarani M. Soverini S, et al. Pharmacogenomics. 2012 Aug;13(11):1271-84. doi: 10.2217/pgs.12.103. Pharmacogenomics. 2012. PMID: 22920397 Review.
• Frequency of BCR-ABL gene mutations in Polish patients with chronic myeloid leukemia treated with imatinib: a final report of the MAPTEST study.

  Lewandowski K, Warzocha K, Hellmann A, Skotnicki A, Prejzner W, Foryciarz K, Sacha T, Gniot M, Majewski M, Solarska I, Nowak G, Wasag B, Kobelski M, Scibiorski C, Siemiatkowski M, Lewandowska M, Komarnicki M. Lewandowski K, et al. Pol Arch Med Wewn. 2009 Dec;119(12):789-94. Pol Arch Med Wewn. 2009. PMID: 20010464